# UroGen Pharma Ltd. (URGN) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from UroGen Pharma Ltd.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/URGN/mda/fy2025/): filed 2026-03-02; accession 0001437749-26-006234 (https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm); latest 10-K
- [FY 2024 MD&A](/company/URGN/mda/fy2024/): filed 2025-03-10; accession 0001437749-25-006842 (https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm)
- [FY 2023 MD&A](/company/URGN/mda/fy2023/): filed 2024-03-14; accession 0001437749-24-007753 (https://www.sec.gov/Archives/edgar/data/1668243/000143774924007753/urgn20231231_10k.htm)
- [FY 2022 MD&A](/company/URGN/mda/fy2022/): filed 2023-03-24; accession 0001437749-23-007710 (https://www.sec.gov/Archives/edgar/data/1668243/000143774923007710/urgn20221231_10k.htm)
- [FY 2021 MD&A](/company/URGN/mda/fy2021/): filed 2022-03-21; accession 0001437749-22-006778 (https://www.sec.gov/Archives/edgar/data/1668243/000143774922006778/urgn20211231_10k.htm)

Back to /company/URGN/